Wolfgang Wick
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
German Consortium on Aggressive Meningiomas (KAM), Ratliff M, Neidert M, Wirsching H, Harter P, Unterberg A, Herold-Mende C, Jungwirth G, Etminan N, Lamszus K, Westphal M, Hänggi D, Jungk C, Mawrin C, Platten M, Snuderl M, Sahm F, von Deimling A, Preusser M, Weller M, Wick W, Acker T, Reifenberger G, Jones D, Pfister S, Frank S, Hench J, Brandner S, Aldape K, Sen C, Golfinos J, Serrano J, Stein M, Dohmen H, Reuss D, Dogan H, Patel A, Blume C, Euskirchen P, Sill M, Schrimpf D, Berghoff A, Sievers P, Hielscher T, Stichel D, Reinhardt A, Suwala A, Grady C, Jones T, Bridges L, Greenway F, Leu S, Jaunmuktane Z, Schittenhelm J, Ketter R, Bewerunge-Hudler M, Rushing E, Ricklefs F, Baumgarten P, Wefers A, Maas S. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. J Clin Oncol 2021; 39:3839-3852.
Oct 7, 2021Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
Oct 7, 2021J Clin Oncol 2021; 39:3839-3852
German Consortium on Aggressive Meningiomas (KAM), Ratliff Miriam, Neidert Marian Christoph, Wirsching Hans-Georg, Harter Patrick N, Unterberg Andreas, Herold-Mende Christel, Jungwirth Gerhard, Etminan Nima, Lamszus Katrin, Westphal Manfred, Hänggi Daniel, Jungk Christine, Mawrin Christian, Platten Michael, Snuderl Matija, Sahm Felix, von Deimling Andreas, Preusser Matthias, Weller Michael, Wick Wolfgang, Acker Till, Reifenberger Guido, Jones David T W, Pfister Stefan M, Frank Stephan, Hench Jürgen, Brandner Sebastian, Aldape Kenneth D, Sen Chandra, Golfinos John, Serrano Jonathan, Stein Marco, Dohmen Hildegard, Reuss David, Dogan Helin, Patel Areeba, Blume Christina, Euskirchen Philipp, Sill Martin, Schrimpf Daniel, Berghoff Anna S, Sievers Philipp, Hielscher Thomas, Stichel Damian, Reinhardt Annekathrin, Suwala Abigail K, Grady Conor, Jones Timothy, Bridges Leslie R, Greenway Fay E A, Leu Severina, Jaunmuktane Zane, Schittenhelm Jens, Ketter Ralf, Bewerunge-Hudler Melanie, Rushing Elisabeth J, Ricklefs Franz, Baumgarten Peter, Wefers Annika K, Maas Sybren L N
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
Sievers P, Etminan N, Ratliff M, Herold-Mende C, Pfister S, Jones D, Weller M, Harter P, Wick W, Preusser M, von Deimling A, Westphal M, Lamszus K, Reifenberger G, Hielscher T, Schrimpf D, Stichel D, Reuss D, Berghoff A, Neidert M, Wirsching H, Mawrin C, Ketter R, Paulus W, Sahm F. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 2020; 140:409-413.
Jul 8, 2020CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
Jul 8, 2020Acta Neuropathol 2020; 140:409-413
Sievers Philipp, Etminan Nima, Ratliff Miriam, Herold-Mende Christel, Pfister Stefan M, Jones David T W, Weller Michael, Harter Patrick N, Wick Wolfgang, Preusser Matthias, von Deimling Andreas, Westphal Manfred, Lamszus Katrin, Reifenberger Guido, Hielscher Thomas, Schrimpf Daniel, Stichel Damian, Reuss David E, Berghoff Anna S, Neidert Marian Christoph, Wirsching Hans-Georg, Mawrin Christian, Ketter Ralf, Paulus Werner, Sahm Felix
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
Nov 27, 2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Nov 27, 2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
Paramasivam N, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister S, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Bewerunge-Hudler M, Schick M, Hübschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers A, Jones D, Gu Z, Werner J, Uhrig S, Wirsching H, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol 2019; 138:295-308.
May 8, 2019Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
May 8, 2019Acta Neuropathol 2019; 138:295-308
Paramasivam Nagarajan, Beck Katja, Brehmer Stephanie, Urbschat Steffi, Seiz-Rosenhagen Marcel, Hänggi Daniel, Herold-Mende Christel, Ketter Ralf, Eils Roland, Ram Zvi, Pfister Stefan M, Wick Wolfgang, Weller Michael, Grossmann Rachel, von Deimling Andreas, Schlesner Matthias, Bewerunge-Hudler Melanie, Schick Matthias, Hübschmann Daniel, Toprak Umut H, Ishaque Naveed, Neidert Marian Christoph, Schrimpf Daniel, Stichel Damian, Reuss David, Sievers Philipp, Reinhardt Annekathrin, Wefers Annika K, Jones David T W, Gu Zuguang, Werner Johannes, Uhrig Sebastian, Wirsching Hans-Georg, Sahm Felix
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
Feb 14, 2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Feb 14, 2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Katz L, Baumgarten P, Herold-Mende C, Wick W, Harter P, Weller M, von Deimling A, Snuderl M, Sen C, Wirsching H, Neidert M, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos J, Reuss D, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 2018; 135:955-963.
Apr 7, 2018Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Apr 7, 2018Acta Neuropathol 2018; 135:955-963
Katz Leah M, Baumgarten Peter, Herold-Mende Christel, Wick Wolfgang, Harter Patrick N, Weller Michael, von Deimling Andreas, Snuderl Matija, Sen Chandra, Wirsching Hans-Georg, Neidert Marian Christoph, Hielscher Thomas, Liechty Benjamin, Silverman Joshua, Zagzag David, Sen Rajeev, Wu Peter, Golfinos John G, Reuss David, Sahm Felix
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 2018; 20:400-410.
Feb 19, 2018Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Feb 19, 2018Neuro Oncol 2018; 20:400-410
Beier Dagmar, Proescholdt Martin, Reinert Christiane, Pietsch Torsten, Jones David T W, Pfister Stefan M, Hattingen Elke, Seidel Clemens, Dirven Linda, Luerding Ralf, Reijneveld Jaap, Warmuth-Metz Monika, Bonsanto Matteo, Bremer Michael, Combs Stephanie E, Rieken Stefan, Herrlinger Ulrich, Kuntze Holger, Mayer-Steinacker Regine, Moskopp Dag, Schneider Thomas, Beringer Andreas, Schlegel Uwe, Stummer Walter, Welker Helmut, Weyerbrock Astrid, Paulsen Frank, Rutkowski Stefan, Weller Michael, Wick Wolfgang, Kortmann Rolf-Dieter, Bogdahn Ulrich, Hau Peter
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
May 3, 2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
May 3, 2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
Nov 22, 2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Nov 22, 2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
Apr 18, 2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Apr 18, 2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Herrlinger U, Reifenberger G, Bamberg M, Sommer C, Tan T, Meyermann R, Wick W, Hundsberger T, Steinbach J, Kortmann R, Blaschke B, Loeser S, Koch D, Rieger J, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7.
Sep 20, 2006Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Sep 20, 2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7
Herrlinger Ulrich, Reifenberger Guido, Bamberg Michael, Sommer Clemens, Tan Ta-Chih, Meyermann Richard, Wick Wolfgang, Hundsberger Thomas, Steinbach Joachim P, Kortmann Rolf-Dieter, Blaschke Britta, Loeser Simon, Koch Dorothee, Rieger Johannes, Weller Michael